KIT (KIT proto-oncogene, receptor tyrosine kinase)

Faggot-like Auer bodies, once considered a hallmark of APL, are not pathognomonic for APL, and diagnosis based solely on morphology is susceptible to misdiagnosis. This report aims to accumulate clinical experience, provide a reference for the diagnosis and management of similar cases, and reduce the incidence of misdiagnosis and missed diagnosis.

Regardless of the limited independent prognostic value of individual CSC markers, their combined expression enhanced risk stratification for recurrence and survival in advanced EOC. Multimarker CSC profiling may enhance prognostication and aid in guiding personalized surveillance and therapeutic strategies.

Although these findings required an urgent repeat marrow evaluation, cytogenetic/molecular testing, and hematology clearance due to the high risk of an indeterminate or pre-leukemic state, the presence of active, refractory gastrointestinal bleeding prompted the immediate initiation of infliximab induction...Severe systemic inflammation can create a reactive bone marrow phenotype indistinguishable from early myeloid neoplasia or myelodysplastic syndrome, posing a life-threatening diagnostic trap. Comprehensive hematologic evaluation-including repeat bone marrow assessment under controlled inflammatory conditions-should be considered mandatory before initiating biologic therapy in patients with CD and unexplained cytopenias or borderline blast counts.

Genome-wide SNP-based LOH profiling reveals distinct, subgroup-specific patterns of chromosomal imbalance in GIST and may serve as a feasible complementary approach to driver mutation analysis for refined molecular characterization and potential future clinical utility.

This case highlights the integration of pathological features, c-kit exon 11 mutation status, and imaging findings in the diagnosis and management of high-risk GSTs. The 4-year recurrence-free survival confirms the effectiveness of risk-stratified adjuvant therapy with imatinib.

This study successfully identified and validated NETs-related biomarkers for MM through machine learning and experimental validation. Understanding the role of NETs-related biomarkers in MM could not only deepen our understanding of the disease but also offer information for clinical applications.

Tyrosine kinase inhibitors (TKI) (midostaurin, avapritinib) have changed the treatment landscape in SM...Cladribine continues to have a role for MC debulking, whereas interferon-α has a diminishing role in the TKI era...Allogeneic stem cell transplant has a role in such patients. Imatinib has a therapeutic role only in the rare patient with an imatinib-sensitive KIT mutation.

Despite overlapping pathological features, uterine and gastrointestinal stromal tumors differ clinically. Surgery is the primary treatment; comprehensive preoperative imaging and postoperative pathological examination are critical to prevent misdiagnosis and optimize management.

Mutation-specific NPM1 IHC is a valuable tool for a rapid assessment of residual morphologic and molecular disease in mid- and postinduction NPM1mut AML.

P-TNTs, which are tightly associated in situ with endothelial-pericyte combined sprouts, appear to play a dual role during vessel collateralization by bridging the gap between distant vessels and guiding vascular outgrowth. The complementary cellular distribution of c-KIT and SCF observed in endothelial cells and pericytes suggests that both endothelial autocrine/paracrine SCF/c-KIT signaling and pericyte-derived paracrine/juxtacrine SCF cues may contribute to the pericyte-driven mode of vessel branching. Similar observations in GB samples further suggest a potential involvement of pericytes and their P-TNTs in tumor vascularization, although sprouting endothelial cells displayed distinct subcellular patterns of c-KIT expression in fetal versus GB tissues.

cytopenias or organomegalies) and shorter PFS and overall survival. Our findings confirm the clinical, genetic and prognostic heterogeneity of SM-AHN and point out its association with the underlying oncogenic profile of neoplastic MC and AHN cells.

P3, N=482, Recruiting, Cogent Biosciences, Inc. | Active, not recruiting --> Recruiting